Cambrian Bio

Cambrian Bio

Private
New York City, New YorkHealthcare & Life Scienceshttp://ww25.cambrian.bio/?subid1=20251210-1246-4735-8194-d5d904c93c24

Last Round

Series C

Oct 26, 2021

Est. Valuation

$497M

Total Funding Raised

$141M

Company Overview

Cambrian Bio is a biotechnology and venture capital company that builds, finances, and manages a portfolio of companies developing therapeutics for age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

age-related disease therapeuticsdistributed development companyDisCohealthspan extensionlongevity biotechanti-aging medicinehub-and-spoke biotechdrug development portfolioclinical-stage biotechdrivers of agingbiotech venture buildergerosciencedrug licensingAMPK activatormTOR inhibitorstelomere lengtheningcell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cambrian Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cambrian Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series COct 26, 2021
VC RoundFeb 9, 2021
UnknownJan 17, 2020

Key People

Founding team and executive leadership

James Peyer

Founder CEO

Founding Team

Cambrian Bio Investors

Notable investors and investment history

InvestorRounds
Future VenturesSeries C, Unknown, VC Round
Galaxy DigitalVC Round, Unknown
Lux CapitalSeries C
Catalio Capital ManagementUnknown, VC Round
Apeiron Investment GroupSeries C, Unknown, VC Round
Infinitas CapitalSeries C
Korify CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2026

    TOR-101 asset is in IND-enabling development for clinical studies.

  • Mar 25, 2026

    ATX-304 is advancing through clinical trials for obesity treatment.

Cambrian Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cambrian Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cambrian Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range27
Year Founded2019
Last FundingOct 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.